DebraPatt,MDMPHMBAExecutiveVicePresident,PolicyandStrategicInitiatives,TexasOncology
Dr.DebraPattisanExecutiveVicePresidentofTexasOncology,aclinicalprofessoratDellMedicalSchool,andabreastcancer
specialistinAustin,Texaswhohasacareerresearchfocusinclinicalcancerinformatics.Shehasresponsibilitiesinhealthcarepolicy
andstrategicinitiativesforherstatewidepracticethatcaresforhalfofTexanswithcancer.Inadditiontoherclinicalworkandresearch
leadership,sheisresponsibleforthestrategicgrowthoftheadvancedpracticeproviderprogram,growthoftelemedicine,andassistsin
managedcare,valuebasedcaremodels,oraloncolytics,publicpolicy,andclinicalinformatics.ShehastestifiedbeforeCongressto
protectaccesstocareforMedicarebeneficiariesandadvocatesforcancerpatientsatthehighestlevelsofthestateandfederal
government.SheisaleaderinclinicalcancerinformaticsandservesastheinauguralEditorinChiefofJCO-ClinicalCancerInformatics
andhasledmultipleinnovativeinformaticsandanalyticsinitiativeswithinTheUSOncologyNetworkwheresheservesasthemedical
directorofanalyticsforMcKessonSpecialtyHealthandisworkingwiththeMckessonteamonacentralized2021analyticsstrategy.Her
informaticsresearchincludesleadingthedevelopmentofclinicaldecisionsupportembeddedwithintheelectronichealthrecordand
workstodevelopelectronicpatientreportedoutcomesembeddedwithinpatientsupporttoolswithinpatientportals.Sheistheprincipal
investigatorforpredictiveanalyticstopredictandreducehospitalizationsinpatientswithadvancedcancer,andparticipatesinthe
precisionmedicineworkgrouptofacilitatedecisionsupportwithintheprecisionmedicinestrategy.
PersonalInfo
LinkedInlinkedin.com/in/debra-patt-md-mph-
mba-274828b
Twittertwitter.com/dapattmd
IntellectualPropertyDevelopment
Chair,PathwaysTaskForce,MSH
PrincipalInvestigator,UsingClinical
DecisionSupporttoImprove
GuidelinebasedDecisionMaking,
MSH
PrincipalInvestigator,Predictive
AnalyticsPilot,MSH
PortalsAdvisoryBoard,MSH
TechnologyandEHRsWorking
Group,ASCO
Experience
2015-12-present
ExecutiveVicePresidentTexasOncology,PolicyandStrategicInitiatives
Responsibilities:
PublicPolicyGuideanddirectpublicpolicyatStateandFederalLeveltoimprovecancer
care.
TestifiedbeforeCongressE&CagainstMedicarepartBpilotprogram,which
waslaterrescinded.
Meetwithpolicymakersasappropriate.
Managerelationshipstosupportcollaborativebusinessagreements.
Managerelationshipswithexternalstakeholders:ASCO,COA,TMA,AMAto
advocateonbehalfofcommunityoncologypatients.
Manageacademicpartnerships(CoPIonGrantswithDellMedicalSchool
andUniversityofNorthCarolinausingtechnologytoenhancecancercare).
StrategicPrioritiesGrowstrategicPriorities:AdvancedPracticeProviders,Telehealth,Oral
Oncolytics,ManagedCare,Assistinreformulationofphysiciancompensation
modeltoincentivizeproductivity,value,andquality.
DevelopingAdvancedPracticeProviderStrategy
DevelopingTelehealthprogram
Workingwithteamtodevelopandsupportoraloncolyticsstrategy
Workingwithmanagedcareteamtoarticulateourvaluepropositionto
payersanddevelopalternativepaymentmodelcontractstoenhancevalue
basedcancercaredelivery.
Workingwiththeprecisionmedicinegrouptounderstandoptimal
implementationstrategyofincorporationofprecisionmedicineintoour
clinicalworkflow.
2007-present
MedicalDirector,PathwaysTaskForceTheUSOncologyNetworkandMSH
Chairthebreastcancerpathwaysandassistthetaskforceininclusionof
therapeuticinterventionswithconsiderationofefficacy,toxicity,andvalue.
PrincipalinvestigatoronCVPclinicaldecisionsupporttooldemonstrationof
improvedadherencetopathwaysprescribingbyintegratingthesoftware
platformintotheelectronichealthrecordandprocessworkflowatpointof
care.
2015-present
MedicalDirector,AnalyticsMcKessonSpecialtyHealth
Assistteamtointegrateanalyticcapabilitieswithintheorganization.
Workswithteamtoidentifynewareasofgrowth,futureretailmodels,
manufacturervalueproposition,needsofspecialtyprograms,andidentify
operatingmodel.
Facilitatedtransitioningfromprojectdirectedapproachestosustained
enterprisemindsetwithgrowthofdisruptiveindustrysolutions.
Evaluateexternalvendorrelationshipsandverticalintegrationacquisitionsto
consideroptimalgrowthstrategies.
WorkwithMCKandMSHtowardacongruentMcKesson2021analytics
strategy.
Principalinvestigatorforpredictiveanalyticspilotstoimprovehealth
outcomesandreducetotalcostofcare.
2016-present
ServiceLineLead,BreastHealth,DivisionofWomen'sHealthServicesDellMedicalSchoolatTheUniversityofTexasatAustin
Leadclinicalintegrationofbreastservicesleadinguptoacancerdiagnosis
forDellMedicalSchool.
LeadtheNC3committeeandprovideupdatesonbreasthealthservices.
Integratecommunitystakeholdersasitpertainstobreasthealth.
2017-present
FullClinicalProfessorDellMedicalSchoolatTheUniversityofTexasatAustin
TeachMedicalStudentsOncologysectionsofthecurriculum.
Workwithmedicalstudentsonresearchprojectstopresentatannual
meetings.
Co-Principalinvestigator:Decisionsupportinbreastcancer.
Co-PrincipalInvestigator:UseofdynamicMRItoevaluateearlyresponders
inbreastcancer.
Co-Chair,AccesstoCareworkinggroup.
2016-present
EditorinChiefJournalofClinicalOncology-ClinicalCancerInformatics
Developalookandfeelforthenewjournal
Assembleaneditorialboardandagroupofassociateeditorswith
complimentaryinformaticsexpertise.
Developrelationshipswithexternalstakeholderorganizationstobuildthe
brand.
2007-2018
MedicalDirector,BreastCancerSetonFamilyofHospitals
Drivegrowthandqualityofbreasthealthservicesthroughthenetworkby
benchmarkingoperationalandqualitymetrics.
Designandlaunchabreastcenter,andplanfornationalaccreditation.
Leadmultidisciplinarytumorboardsforbreastcancer.
Leadqualityimprovementprojectsforbreastcancerforthenetworkand
reporttothecancercommittee.
2008-2015
MedicalDirector,HealthcareInformaticsandHEORTheUSOncologyNetworkandMckessonSpecialtyHealth
Businessdevelopmentfrom2studiesatatimeto22studiesatatime.
Grewteamofanalystsandbusinessdevelopmentlead.
Developedaninternalchartreviewprocess.
Developedstreamlinedprocessworkflowandqualityimprovementprocesses.
IncreasedbrandawarenessofTheNetworkthroughmultiplepresentations
andpublications.
2006-2007
AdjunctProfessorMDAndersonCancerCenter,DivisionofCancerMedicine
AdministeredYoungInvestigatorsAwardGranttoconducthealthservices
researchinelderlypatientswithbreastcancertoevaluatelongtermtoxicities
associatedwithtreatment.
Education
2012-2014
TheUniversityofTexasatAustin,MccombsSchoolofBusiness,MastersinBusinessAdministration
2012-present
TheUniversityofTexasSchoolofPublicHealthABD
PhDPrograminHealthEconomicsandHealthServicesResearch
AnticipatedcompletionDecember,2018
Researchon"Evaluatingtheimpactonclinicaldecisionsupportsystemsto
nudgecompliancewithevidencebasedpathwaysinpatientswithcancerby
usingmixedeffectsmodels."
2000-2006
TheUniversityofTexasSchoolofPublicHealth,MastersinPublicHealthManagementandPolicySciences
2003-2006
MDAndersonCancerCenterFellowshipinHematologyandMedicalOncology
2005-2005
NationalCancerInstituteSummerFellowshipPrograminCancerPrevention
1999-2003
BaylorCollegeofMedicineResidencyinInternalMedicineandPediatrics
1995-1999
BaylorCollegeofMedicineDoctorateofMedicine
1992-1995
TheUniversityofTexasatAustin,ZoologyPlanIHonorsProgram,BS
ActiveResearch
2017 ImplementationofadvancedMRIinthecommunitysettingforpredictingthe
responseofbreastcancertoneoadjuvanttherapy.LeadPI:DrThomas
Yankeelov,SitePI:DrDebraPatt
2018 ProjectLONESTARevaluatingelectronicpatientreportedoutcomesin
communitypractice.COPIs:Dr.EthanBaschandDr.DebraPatt
2018 Modelingpredictiveanalyticstoevaluateriskof30dayhospitalizationin
patientswithadvancedcancer.
2015 Utilizingclinicaldecisionsupportsystemswithintheelectronichealthrecord
tofacilitatecompliancewithevidencebasedpathwaysforcancercare.
2018 UsingclinicalpharmacistinitiatedoralantiemeticprotocolstocontrolCINV
andenhancevalueincancercare.
LeadershipDevelopment
2013-2014
ASCOLeadershipDevelopmentProgramASCOHQ,Alexandria,VA
Ayearlongprogramofyoungnationalleadersinoncologywherewelearned
leadershipdevelopmentandpartnershipwithstakeholders.
2013 McKessonSpecialtyHealthTier2LeadershipDevelopmentProgram
2014-2016
McKessonSpecialtyHealthTier3LeadershipDevelopmentProgramLaunchedTelehealthpilotinTexasOncology
2015 TexasOncologyLeadershipDevelopmentProgram
Awards
2018SubmittedasCo-PrincipalInvestigator,NCIgranttoutilizeelectronic
patientreportedoutcomesinstrumentswithinastatewideoncologypractice
(SubmittedwithDr.EthanBasch,UNC)
2018SubmittedasCo-PrincipalInvestigator,NCIgranttousedynamicMRIto
evaluateearlyresponsetochemotherapyinlocalizedbreastcancer
(SubmittedwithDr.TomYankeelov,UTAustin)
2014RuthBainesYoungPhysicianoftheYearAward,TravisCountyMedical
Society
2006AmericanSocietyofClinicalOncologyYoungInvestigatorsAward
2006ResearchFellowoftheyear,MDAndersonCancerCenter
2006AmericanSocietyofClinicalOncologyMeritAward
2006JesseJonesFellowshipinCancerEducationandPreventionatMD
AndersonCancerCenter-theannualeducationandpreventionawardgiven
toonefellowwhohasdemonstratedexcellenceintheseareas.
Certificates
2003 TexasStateMedicalLicense
2003 AmericanBoardofInternalMedicine
2006 AmericanBoardofInternalMedicine,OncologySpecialtyExam
2017 AmericanBoardofInternalMedicineOncologySpecialtyExamRecertification
2007 AmericanBoardofInternalmedicine,HematologySpecialtyExam
BoardandCommitteeActivity
2017-present
ASCONominatingCommittee
2016-present
CommunityOncologyAllianceBoardofDirectors
2014-present
ASCOClinicalPracticeCommittee,Chair
2017-2017
ASCOEducationCommittee
2011-2016
PublicationsandOutcomesCommitteeChair,MSH
2011-present
USOncologyNationalPolicyBoard
2009-2015
TexasMedicalAssociationCancerCommittee,Chair
2015-2016
TexasMedicalAssociationCommitteeonScienceandPublicHealth
2016-present
TexasMedicalAssociation,CouncilonLegislation
2017-present
ASCOEHR,technology,anddataworkinggroup
2015-2017
KomenAustinBoardofDirectors
2011-2014
BreastCancerResourceCenterBoardofDirectors
2006-present
AdvisoryCounciloftheTexasCancerRegistry
2008-present
PharmacyandTherapeuticsCommittee,USON
2011-present
CollaborativeCareCommittee,MSH
2011-2017
PatientPortalandOncologyPortalWorkingGroup,MSH
2017-present
COAGovernmentRelationsCommittee
2017-present
COAPaymentReformCommittee
2014-present
ASCOPaymentReformandPolicyCommittee
Publications
PattD."DebraPattonHowtheManagementofCancerisChangingas
PatientsLiveLonger."Oncology(WillistonPark).2018Jun15
RamakrishnaN,TeminS,ChandarlapatyS,CrewsJR,DavidsonNE,Esteva
FJ,GiordanoSH,KirshnerJJ,KropIE,LevinsonJ,ModiS,PattDA,
PerlmutterJ,WinerEP,LinNU."RecommendationsonDiseaseManagement
forPatientsWithAdvancedHumanEpidermalGrowthFactorReceptor2-
PositiveBreastCancerandBrainMetastases:ASCOClinicalPractice
GuidelineUpdate."JClinOncol.2018Jun25
GiordanoSH,TeminS,ChandarlapatyS,CrewsJR,EstevaFJ,KirshnerJJ,
KropIE,LevinsonJ,LinNU,ModiS,PattDA,PerlmutterJ,RamakrishnaN,
WinerEP,DavidsonNE."SystemicTherapyforPatientsWithAdvanced
HumanEpidermalGrowthFactorReceptor2-PositiveBreastCancer:ASCO
ClinicalPracticeGuidelineUpdate."JClinOncol.2018Jun
25:JCO201879269
DenduluriN,LymanGH,WangY,MorrowPK,BarronR,PattD,BhowmikD,
LiX,BhorM,FoxP,DhandaR,SaravananS,JiaoX,GarciaJ,CrawfordJ.
“ChemotherapyDoseIntensityandOverallSurvivalAmongPatientsWith
AdvancedBreastorOvarianCancer.”ClinBreastCancer.2018
SoraceAG,WuC,BarnesSL,JarrettAM,AveryS,PattD,GoodgameB,
LuciJJ,KangH,AbramsonRG,YankeelovTE,VirostkoJ.“Repeatability,
reproducibility,andaccuracyofquantitativemriofthebreastinthecommunity
radiologysetting.”JMagnResonImaging.2018
PattD,PageR.“MeasuringQualityIsComplicated.”JOncolPract.2017
VirostkoJ,HainlineA,KangH,ArlinghausLR,AbramsonRG,BarnesSL,
BlumeJD,AveryS,PattD,GoodgameB,YankeelovTE,SoraceAG.
“Dynamiccontrast-enhancedmagneticresonanceimaginganddiffusion-
weightedmagneticresonanceimagingforpredictingtheresponseoflocally
advancedbreastcancertoneoadjuvanttherapy:ameta-analysis.”JMed
Imaging(Bellingham).2018
PattDA“Utilizationmanagementinoncology”JClinOncol.2017;35(suppl
8S;abstract172).
CookeKJ,PattDA,PrabhuRS.“TheRoadofMentorship.”AmSocClin
OncolEducBook.2017;37:788-792.
PattDA,BernstamEV,MandelJC,KredaDA,WarnerJL.“MoreMedicine,
FewerClicks:HowInformaticsCanActuallyHelpYourPractice.”AmSocClin
OncolEducBook.2017;37:450-459
RobertNJ,GoertzHP,ChopraP,JiaoX,PattD,AntaoV“Her2-positive
metastaticbreastcancerpatientsreceivingpertuzumabinacommunity
oncologypracticesetting:Treatmentpatternsandoutcomes”DrugsReal
WorldOutcomes2017
AgiroA,MaQ,AchesonAK,WuSJ,PattDA,BaronJJ,MalinJ,SchilskyRL,
LymanGH“RiskofNeutropenia-RelatedHospitalizationinPatientsWho
ReceivedColony-StimulatingFactorswithChemotherapyforBreastCancer”
JClinOncol2016
PattD“BetterScreeningUsingBigData”JOncolPract2016Aug;12(8):699-
700
LiangC,LiL,FraserCD,KoA,CorzoD,EngerC,PattD“Thetreatment
patterns,efficacy,andsafetyofnab-paclitaxelforthetreatmentofmetastatic
breastcancerintheUnitedStates:resultsfromhealthinsuranceclaims
analysis”BMCCancer2015
DenduluriN,PattDA,WangY,BhorM,LiX,FavretAM,MorrowPK,Barron
RL,AsmarL,SaravananS,LiY,GarciaJ,LymanGH.DoseDelays,Dose
Reductions,andRelativeDoseIntensityinPatientsWithCancerWho
ReceivedAdjuvantorNeoadjuvantChemotherapyinCommunityOncology
Practices.JNatlComprCancNetw.2015
YasenchakCA,TsengWY,YapM,RembertD,PattDA.“Economicimpactof
diseaseprogressionfollowingfront-linetherapyinclassicalHodgkin
lymphoma.”LeukLymphoma2015
SchadendorfD,HodiFS,RobertC,WeberJS,MargolinK,HamidO,PattD,
ChenTT,BermanDM,WolchokJD.“PooledAnalysisofLong-TermSurvival
DataFromPhaseIIandPhaseIIITrialsofIpilimumabinUnresectableor
MetastaticMelanoma”JClinOncol2015
RamakrishnaN,TeminS,ChandarlapatyS,CrewsJR,DavidsonNE,Esteva
FJ,GiordanoSH,Gonzalez-AnguloAM,KirshnerJJ,KropI,LevinsonJ,Modi
S,PattDA,PerezEA,PerlmutterJ,WinerEP,LinNU.“Recommendationson
DiseaseManagementforPatientsWithAdvancedHumanEpidermalGrowth
FactorReceptor2-PositiveBreastCancerandBrainMetastases:American
SocietyofClinicalOncologyClinicalPracticeGuideline.“JClinOncol.2014
GiordanoSH,TeminS,KirshnerJJ,ChandarlapatyS,CrewsJR,Davidson
NE,EstevaFJ,Gonzalez-AnguloAM,KropI,LevinsonJ,LinNU,ModiS,
PattDA,PerezEA,PerlmutterJ,RamakrishnaN,WinerEP.“Systemic
TherapyforPatientsWithAdvancedHumanEpidermalGrowthFactor
Receptor2-PositiveBreastCancer:AmericanSocietyofClinicalOncology
ClinicalPracticeGuideline.”JClinOncol.2014
PattDA“Takingonracialandethnicdisparitiesincancercare”JCommunity
andSupportiveOncology2014
Reeder-HayesK,FelipE,PattD,JaffeeE.“Womeninoncology”AmSocClin
OncolEduc.Book2013;448-55.2013
RamseySD,SullivanSD,ReedSD,TinaShihYC,SchaecherK,DhandaR,
PattD,PendergrassK,WalkerM,MalinJ,SchwartzbergL,NeumannK,Yu
E,RaveloA,SmallA.“Oncologycomparativeeffectivenessresearch:a
multistakeholderperspectiveonprinciplesforconductandreporting.”
Oncologist2013;18(6):760-7.EpubMay6,2013
BrowM,OkonT,GeorgeE,EagleD,PattD,GouldB,BrooksB,CobbP,
WhiteC,TetraultS,BeveridgeR.“Thoughtsandrecommendationsoncancer
caresiteofservice”CommunityOncology20129(2)pages382-385.
BrowM,HovermanJR,PattD,HermanB,VerrilliD,GareyJ,BeveridgeR.
“Definingcancercarequalityordeliveringqualitycancercare?”JNatlCompr
CancNetw.2013Feb1;11(2):121-4.
Chen,C,Dhanda,R,Tseng,W,Forsyth,M,Patt,D.“EvaluatingUse
CharacteristicsfortheOncotypeDX21-generecurrencescoreand
concordancewithchemotherapyuseinearlystagebreastcancer”JOncol
PractFeb2013
KolodziejM,HovermanJR,GareyJS,EspiritoJ,ShethS,GinsburgA,
NeubauerMA,PattD,BrooksB,WhiteC,SitarikM,AndersonR,Beveridge
R.“Benchmarksforvalueincancercare:ananalysisofalargecommercial
population.”JOncolPract.2011
PattD,EspiritoJ,TurnwaldB,HovermanJ,NeubauerM,CartwrightT,Busby
L,BrooksB,SitarikM,KolodiejM,BeveridgeR.”Changesinadjuvantbreast
cancerchemotherapyregimenselectionovertimeinthecommunity”May30,
2012:6109.PublishedinJCOsupplements
PattD,EspiritoJ,TurnwaldB,HovermanJ,NeubauerM,BusbyL,Brooks,
Kolodziej,AndersonR,BeveridgeR“Utilizationofpegfilgrastiminadjuvant
chemotherapyregimensforbreastcancerinthecommunity”Sep30,
2011:213PublishedinJCOsupplements
ChenC,PattD,KazzazD,ShankletonJ,ForsythM,GaneshR.“Evaluating
utilizationcharacteristicsfortheOncotypeDXrecurrencescoreinearly-stage
breastcancer”Jun9,2011:625.PublishedinJCOsupplements
GinsburgA,PattD,FlinnJ,EspiritoJ,NeubauerM,CartwrightT,Hoverman
J,BusbyB,Brooks,BKolodziejM,SitarikM,AndersonR,BeveridgeR.
“Understandingmalebreastcancerinthecommunitysetting”ASCO
MEETINGABSTRACTSJun9,2011:e16526PublishedinJCOsupplements
PattD,EspiritoJ,TurnwaldB,HovermanJ,NeubauerM,CartwrightT,
BrooksB,BusbyL,SitarikM,KolodziejM,GinsburgA,ShethS,GareyJ,
ClaytonM,NelsonR,AndersonR,BeveridgeR.“Utilizationandrelativevalue
ofbreastcanceradjuvantchemotherapyregimensinthecommunity”Jun9,
2011:e16595.PublishedinJCOsupplements
Hoverman,JR.CartwrightTH.Patt,DA.Espirito,JL.Clayton,MP.Garey,JS.
Kopp,TJ.Kolodziej,M.Neubauer,M.Fitch,K.Pyenson,B.Beveridge,RA.
“Pathways,Outcomes,andCostsinColonCancer:Retrospectiveevaluations
intwodistinctdatabases”JournalofOncologyPracticeMay2011.
O’Shaughnessy,J.Osborne,C.Pippen,JE.Yoffee,M.Patt,D.RochaC.Koo,
IC.ShermanBM.Bradley,C.“IniparibplusChemotherapynMetastaticTriple-
NegativeBreastCancer”NEJM2011Jan20;364(3):205-14.Epub2011Jan
5
Socinski,MA.Raju,RN.Stinchombe,T.Kocs,DM.Couch,LS.Barrera,D.
Rousey,SR.Choksi,JK.Jotte,R.Patt,DA.Periman,PO.Schlossberg,HR.
Weissman,CH.Wang,Y.Asmar,L.Pritchard,S.BromundJ.Peng,G.Treat,
J.Obasaju,CK.“RandomizedphaseIItrialofpemetrexedandcarboplatin
withorwithoutenzastaurinversusdocetaxelandcarboplatinasfirst-line
treatmentofpatientswithstageIIIB/IVnon-smallcelllungcancer”JThorac
Oncol2010
Scholl,P.Snyder,N.Patt,D.Talbott,B.“Pilomatricalcarcinosarcoma”
Otolaryngology-HeadandNeckSurgery2010143,s36-37.
Patt,D,Espirito,J,Turnwald,B,Hoang,S,Hoverman,J.“Ixabepilonealone
andincombinationwithchemotherapyinthecommunitysetting”Proceedings
ASCOBreastCancerSymposium.Abstract204.2010.
Neubauer,MA.Espirito,JL,Clayton,M.Patt,DA.“Combinationversus
sequentialchemotherapyformetastaticbreastcancer:Anevaluationof
outcomesfromacommunityoncologynetwork”JCO28:15s,2010(suppl;
abstr6106).
PattD,ZhigangD,ShenyingF,HortobagyiG,GiordanoS.“AcuteMyeloid
LeukemiaafterAdjuvantBreastCancerTherapyinOlderWomen:
UnderstandingRisk”JCO2007September125(25)3871-6.
Patt,DebraandGiordano,SharonH.“PaclitaxelinBreastCancer”Women’s
HealthJanuary2006Jan.2:1(11)11-21
Patt,D,GoodwinJ,Kuo,Y,FreemanJ,ZhangD,BuccholzT,HortobagyiG,
GiordanoS.“Cardiacmorbidityofadjuvantradiotherapyinpatientswithearly
stagebreastcancer”JCO2005.October20.23(30)7475-82.
PattD,ShoplandD,AndersonC,BurnsD,DunningtonJ,GritzE.“Trendsto
protectworkersfromjobrelatedsecondhandsmokeinTexas”Texas
Medicine.2005Dec;101(12):50-6.